SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-20-181113
Filing Date
2020-06-26
Accepted
2020-06-26 17:08:09
Documents
7
Period of Report
2020-05-28
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A d947173d8ka.htm 8-K/A 24160
2 EX-23.1 d947173dex231.htm EX-23.1 1996
3 EX-99.1 d947173dex991.htm EX-99.1 81374
4 EX-99.2 d947173dex992.htm EX-99.2 333772
5 EX-99.3 d947173dex993.htm EX-99.3 235278
6 EX-99.4 d947173dex994.htm EX-99.4 172362
7 EX-99.5 d947173dex995.htm EX-99.5 245002
  Complete submission text file 0001193125-20-181113.txt   1095215
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

IRS No.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-36510 | Film No.: 20994993
SIC: 2834 Pharmaceutical Preparations